Blog

Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations

Photoof Erman Akkus from X

May 6, 2024, 19:10

Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations

Erman Akkus, medical oncologist at Ankara Medical University, shared on Twitter/X:

“Metastatic NSCLC without oncogenic alterations
ASCO Educational Book

ICI as Monotherapy
ICI as Combination Treatment
ICI-ICI Combination Treatments
Clinical Decision Questions:
Best Approach in PD-L1≥50%
Role for Dual Checkpoint Blockade
Discontinuation Strategies in Long-term Responders to ICI
Second-Line Treatments
Future Approaches
Antibody-drug Conjugates
Chemotherapy-free First-Line Treatments.”

Visit the article website.
Source: Erman Akkus/X

Antibody drug conjugates ASCO cancer cancer treatment Check point Inhibitors chemotherapy Clinical Decision Making combination therapy Erman Akkus immunotherapy Long Term Responders Lung cancer medical oncology monotherapy NSCLC OncoDaily oncogenic alterations Oncology PD-L1 Treatment Strategies

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage